The comparison and validity of troponin I assay systems in diagnosing myocardial ischemic injury after surgical coronary revascularization by Martin, C. B. et al.
d
a
(
S
a
p
o
s
t
s
p
m
g
o
m
f
t
P
D
b
i
v
h
d
a
o
t
e
C
(
b
t
n
a
s
†
U
M
T
H
m
2The Comparison and Validity of Troponin I Assay Systems in Diagnosing
Myocardial Ischemic Injury After Surgical Coronary Revascularization
C. Bruce Martin, MBBS, FRCA,* Andrew D. Shaw, MBBS, FRCA,* Janos Gal, MD, PhD,*
Natarajan Aravindan, PhD,* Frank Murphy, MPath,† David Royston, MBBS, FRCA,and Bernhard J. Riedel, MBChB, FCA, MMed, FAHA*
t
w
s
r
t
B
t

i
i
c
t
e
c
a
©
K
eObjective: A prospective observational study was con-
ucted to test the agreement between 2 commercially avail-
ble automated cardiac troponin-I immunoassay systems
Opus Plus, Behring Diagnostics UK Ltd, Hounslow, UK; Ax-
YM, Abbott Laboratories, Abbott Park, IL) and to determine
normal reference range and threshold value indicative of
erioperative myocardial infarction (PMI) after elective cor-
nary artery bypass graft (CABG) surgery for the Opus Plus
ystem.
Design: Prospective, observational study.
Setting: Single institution, cardiothoracic specialty hospi-
al.
Participants: Seventy patients undergoing elective CABG
urgery.
Interventions: After institutional review board approval,
atients received standardized anesthetic, surgical, and
yocardial preservation techniques. Serial electrocardio-
raphs, creatine kinase–MB, troponin-I, and perioperative
utcome data were collected. Correlation between the im-
unoassay systems was tested using 124 duplicate samples
rom the first 18 patients. The normal reference range and
hreshold value indicative of PMI were tested for the Opust
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88 Journal of CardiothorMeasurements and Main Results: Peak troponin-I concen-
rations (median [interquartile range]) differed significantly
hen measured by the Opus Plus and AxSYM immunoassay
ystems (5.61 [3.20-22.35] g/L v 46.50 [14.55-70.95] g/L,
espectively; p < 0.001). There was clear proportional bias
hat was corrected with log transformation of the raw data.
y using confidence interval and receiver operating charac-
eristic curve analysis, the authors showed that a value >15
g/L was indicative of PMI (Opus Plus system) and accord-
ngly report a 35.7% (2.9% Q-wave) overall incidence of PMI
n this study population (n  70).
Conclusions: These data highlight differences between
ommercially available troponin-I assay systems. The au-
hors recommend that each institution establish a local ref-
rence range and threshold indicative of perioperative myo-
ardial infarction for its specific patient population and
ssay system and provide sample methodology.
2005 Elsevier Inc. All rights reserved.
EY WORDS: coronary artery bypass graft surgery, periop-
rative myocardial infarction, troponin-I, receiver operatinglus system using duplicate samples from all 70 patients. characteristic curve analysisESPITE ADVANCES IN myocardial protective strate-
gies, ischemic injury often complicates coronary artery
ypass graft (CABG) surgery. Accurate diagnosis and timely
ntervention of perioperative myocardial infarction (PMI) are
ital because major ischemic injury is associated with reduced
ospital1-4 and long-term5,6 survival. Similarly, more recent
ata suggest that minor ischemic injury after CABG surgery is
lso associated with adverse short-term7,8 and medium-term9
utcome. Accurate assessment of ischemic injury will facilitate
he comparison and optimization of myocardial protective strat-
gies with further improved surgical outcome.
The Joint European Society of Cardiology/American College of
ardiology Committee for redefinition of myocardial infarction
MI) currently considers cardiac troponin isozyme (cTn) as the
iomarker of choice for myocardial injury.10 This is on account of
he improved sensitivity and specificity of cTn for acute MI, both
onsurgical11,12 and perioperative7,13-17 and for reperfusion injury
fter thrombolysis.18 The consensus document, however, fails to
et standard criteria for PMI after cardiac surgery.
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nited Kingdom.
Address reprint requests to Bernhard J. Riedel, MBChB, FCA,
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he University of Texas M.D. Anderson Cancer Center, 1515
olcombe Boulevard, Houston, TX, 77030. E-mail: briedel@
danderson.org
© 2005 Elsevier Inc. All rights reserved.
1053-0770/05/1903-0003$30.00/0After the introduction of a commercially available automated
roponin-I (cTn-I) immunoassay system into the authors’ clin-
cal laboratory and based on the lack of standardization be-
ween such systems, a prospective observational study was
onducted to (1) test the hypothesis that there would be no
ifference between 2 commercially available cTn-I immunoas-
ay systems (Opus Plus analyser, Behring Diagnostics UK Ltd,
ounslow, UK; AxSYM Immunoassay system, Abbott Labo-
atories, Abbot Park, IL), and (2) establish a normal reference
ange for the cTn-I system (Opus Plus) implemented at the
uthors’ institution. This reference range would be representa-
ive of patients who did not suffer a PMI after elective CABG
urgery, with a value above the upper limit of this reference
ange being indicative of troponin release consequent to isch-
mic injury rather than surgical manipulation.
METHODS
After institutional review board approval, informed consent was
btained from 70 consecutive patients scheduled for elective CABG
urgery. Inclusion criteria consisted of significant stenosis in at least 2
oronary arteries with preserved left ventricular systolic function. Ex-
lusion criteria were acute preoperative MI (within 7 days of surgery),
reexisting conduction or rhythm abnormalities (such as left bundle-
ranch block, atrial fibrillation), and revision surgery or the need for a
ombined surgical procedure (such as CABG and carotid endarterec-
omy or valvular surgery).
All previously prescribed medications were continued preopera-
ively. Anesthesia was induced with propofol (1-2 mg/kg), fentanyl
8-10 g/kg), and pancuronium bromide (0.15 mg/kg) used for muscle
elaxation. Before, during, and after nonpulsatile cardiopulmonary by-
ass (CPB), anesthesia was maintained with isoflurane (0.5-1 minimum
lveolar concentration) and a propofol infusion (3 mg/kg/h). Propofol
as continued in the intensive care unit (ICU) until patients met
acic and Vascular Anesthesia, Vol 19, No 3 (June), 2005: pp 288-293
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289TROPONIN I ASSAY SYSTEMStandard criteria for extubation. All patients received an intravenous
nfusion of nitroglycerin (0.3 g/kg/min) from the time of induction of
nesthesia through to the first postoperative day.
Before CPB, all patients received systemic anticoagulation using
nfractionated heparin (300 IU/kg) to achieve an activated coagulation
ime 480 seconds. A nonpulsatile flow (2.4 L/min/m2) was achieved
uring CPB using a roller pump (Cobe Stockert; Stockert Instrument,
ungis, France) and a membrane oxygenator (Sorin Laboratories,
irandola, Italy). The myocardial preservation protocol included mod-
rate systemic hypothermia (nasopharyngeal temperature of 32°C-
4°C), cold anterograde hyperkalemic crystalloid (St. Thomas’s I)
ardioplegia solution, and topical cooling of the myocardium with
ce-slush placed within the pericardial sac. Cardioplegia was repeated
t 30-minute intervals or earlier if electrical activity was observed
uring electrocardiogram (ECG) monitoring. All patients received a
eft internal mammary artery graft to the left anterior descending or
iagonal coronary artery, and additional saphenous vein grafts were
laced where required. Once surgery was complete, patients were
ewarmed to 37°C, weaned from CPB, and the residual effects from
eparin neutralized with protamine sulfate. After achieving hemostasis
nd chest closure, patients were transferred to the ICU.
Serial creatine kinase (CK) and CK-MB isoenzyme levels were
easured preoperatively and at 3, 6, 12, 24, 72, and 120 hours (day 5)
fter reperfusion (defined as cross-clamp release at completion of the
nal distal coronary anastomosis). Blood samples were collected in
ithium heparin tubes, stored at 4°C, and analyzed within 24 hours
sing an immunoinhibition and immunoprecipitation method (Sigma
iagnostics, St Louis, MO). The normal reference range for total CK
n a nonsurgical population is195 IU/L and170 IU/L for males and
emales, respectively. In the authors’ laboratory, the upper limit of
ormal for CK-MB is 24 IU/L for both sexes. Intra-assay and
nterassay variability is 2.6% and 5.4%, respectively.
cTn-I protein concentrations were measured preoperatively and at 3, 6, 12,
4, 72, and 120 hours (day 5) after reperfusion. Blood samples were collected,
llowed to coagulate, and then centrifuged at 3,500 rpm for 15 minutes at 4°C.
Fig 1. Bland–Altman plot of assay
omparison. Data shows clear propor-
ional bias. Opus Plus and AxSYM on
he x and y axis represent cTn-I concen-
rations measured by these assay sys-
ems, respectively.erum was then stored at 0°C until assays were performed.To investigate the extent of agreement between different cTnI as-
ays, the Opus Plus and the AxSYM methods were compared using 124
uplicate samples from the first 18 patients. Thereafter, serum samples
rom all 70 patients were analyzed using the Opus Plus method to
etermine a local reference range and thus establish a threshold indic-
tive of PMI after elective CABG surgery for the authors’ institution.
The Opus Plus method uses a fluorogenic enzyme-linked, 2-site
sandwich) immunoassay technique with goat polyclonal antibodies to
roponin. The AxSYM method uses a microparticle enzyme immuno-
ssay technique with mouse monoclonal antibodies to the cardiac
soform of troponin I. Intra-assay and interassay variability is 5.0% and
.3% and 4.4% and 6.3% for the Opus Plus and AxSYM methods,
espectively. For both assays, 0.5 g/L is given as the normal
eference range for apparently healthy individuals and 2.0 g/L the
iagnostic cutoff for acute MI in the nonsurgical population.
Serial 12-lead ECGs were recorded preoperatively and again on
ostoperative days 1, 3, and 5. Two independent physicians, blinded to
he laboratory data, interpreted the electrocardiograms. If a consensus
ould not be reached, the opinion of a third physician was obtained.
PMI was diagnosed when the following ECG and CK-MB criteria
ere met:
. ECG changes according to the Minnesota code criteria19
a. Q-wave PMI: the appearance of new and persistent Q-waves
0.04 seconds in duration in at least 2 contiguous leads or
equivalent R-wave increments leading to an R/S ratio of 1 in
leads V1 and V2 of the standard 12-lead ECG.
b. Non–Q-wave PMI: the appearance of new and persistent (24
hours) conduction abnormalities or ST-T alterations (ST-seg-
ment depression or elevation 0.1 mV at 0.08 seconds after the
J-point or T-wave inversion) in at least 2 contiguous leads of the
standard 12-lead ECG.
. CK-MB activity 50 IU/L lasting for more than 12 hours20-22 or
occurring after 21 hours of reperfusion.23
hen only one ECG or CK-MB criterion was met, PMI status was
egarded as “undefined.”Data relating to the need for cardiovascular support, incidence of
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290 MARTIN ET ALostoperative atrial fibrillation (requiring treatment), duration of me-
hanical ventilation, ICU length of stay, and hospital length of stay
ere recorded. Cardiovascular support was defined as the requirement
or inotropic support (dopamine, 3 g/kg/min, or epinephrine infu-
ion), pacing, or antiarrhythmic therapy for malignant arrhythmias.
Data are presented as mean  standard error of the mean or as a
ercentage of the study group unless stated otherwise. To evaluate
greement between the 2 commercially available cTn-I assays, data
ere analyzed using the method of Bland and Altman.24,25 Parametric
nd nonparametric data were analyzed using the appropriate test (eg,
npaired t test for continuous parametric variables, Fisher exact test for
ategoric variables, and Mann-Whitney U test for nonparametric vari-
bles.) One-way analysis of variance or Kruskal-Wallis tests were
erformed to assess the statistical significance of observed differences
etween multiple groups. Receiver operating characteristic (ROC)
urves were plotted to assess the utility of troponin measurement for
iagnosis of PMI. In all cases, a p value of 0.05 was regarded as
tatistically significant. Analyses were performed using GraphPad
rism version 3.00 (GraphPad Software Inc, San Diego, CA) and Excel
000 (Microsoft Inc, Redmond, WA) with the Analyse-It add-in (Ana-
yse-It Ltd, Leeds, UK).
RESULTS
All patients had normal preoperative CK-MB (24 IU/L)
nd cTn-I (2 g/L) values. In addition, preoperative cTn-I
oncentrations did not differ significantly between groups.
One hundred twenty-four duplicate samples were analyzed
rom the first 18 patients. Peak cTn-I protein concentrations
median [interquartile range]) differed significantly (5.61 [3.20-
2.35] g/L v 46.50 [14.55-70.95] g/L; p  0.001) when
easured using the Opus Plus and AxSYM assay systems, pespectively. Although good correlation (R2  0.7) was ob-
erved between the 2 assay systems, the Bland-Altman plot of
he data revealed clear proportional bias (Fig 1) that corrected
n log transformation of the raw data (Fig 2). According to the
pus Plus assay, 5 of 18 patients had peak cTn-I values
uggestive of PMI (15 g/L, see later). However, 3 of these
atients had values below the median peak cTn-I value (46.5
g/L) for the AxSYM assay. Furthermore, 2 patients with peak
Tn-I values 15 g/L by the Opus Plus method had excep-
ionally high (80 g/L) peak cTn-I values when measured by
he AxSYM method.
After CABG surgery, the 70 patients were divided into 1 of
groups according to whether or not they met the predefined
riteria for PMI based on CK-MB and ECG changes (see
ethods). The groups consisted of non-PMI (n  40, 57.1%),
MI (n  9, 12.9%), and undefined (n  21, 30.0%). Of the 9
atients with PMI, 2 (2.9%) patients suffered a Q-wave PMI,
nd 7 (10.0%) patients suffered a non–Q-wave PMI.
Demographic and intraoperative data for the 3 patient groups
non-PMI, undefined, and PMI) are summarized in Table 1.
roups were similar in terms of the sex ratio, age, weight,
reoperative comorbid risk factors, medications, angina score,
reoperative ventricular function, and number of stenosed cor-
nary arteries. Intraoperative data, including number of coro-
ary arteries grafted and duration of CPB and aortic cross-
lamping, were also similar between groups. All patients had a
ood clinical outcome with no incidence of malignant arrhyth-
ia, cardiac failure, or need for intra-aortic balloon counter-
Fig 2. Bland-Altman plot of
assay comparison with correc-
tion of bias by log-transforma-
tion. Opus Plus and AxSYM on
the x and y axis represent cTn-I
concentrations measured by
these assay systems, respec-
tively.ulsation. There were no perioperative deaths, and all patients
st
m
a
v
h
(
u
t
c
o

P
r
t
n
v
v
g
u WMA
291TROPONIN I ASSAY SYSTEMSurvived to hospital discharge. Peak cTn-I concentration and
ime to peak cTn-I concentration according to the Opus Plus
ethod for the 3 groups are presented in Table 2.
Assuming a normal/Gaussian distribution for most clinical
ssay data, the upper limit of “normal” is defined as the mean
alue plus 1.96 SD (ie, at the 97.5th percentile). However, it
as recently been suggested that a value of mean plus 3 SD
99.5th percentile) defines this upper limit of a “normal” pop-
lation more accurately.26 Using these definitions, in the au-
hors’ laboratory the upper reference limit for “normal” peak
Tn-I protein concentration after uncomplicated on-pump cor-
nary revascularization is 15.7 g/L (97.5th percentile) and 20
g/L (99.5th percentile), respectively, as reflected by the non-
MI group. Accordingly, values below or above the upper
eference limit would most likely be representative of surgical
rauma or ischemic myocardial injury, respectively.
Because, in this case, there is no meaning for a lower limit of
ormal, the ROC curve method is suitable as a means of
Table 1. Demographic Data of N
Non-PMI
Patients, no. (%) 40 (57.1)
Sex ratio 92.5% male
Age (y) 59.0  1.3
Weight (kg) 80.0  2.0
Preoperative comorbidities (%)
Hypertension 35.0
NIDDM 12.5
Hypercholesterolemia 67.6
Preoperative therapy (%)
Aspirin 70.0
Ca2 antagonists 50.0
Nitrates 45.0
ACE inhibitors 12.5
Diuretics 7.5
-blockers 72.5
Angina (CCSC)
I-II 80.0
III-IV 20.0
Previous MI 62.5
Angiography
SWMA 26.9
LVEF  50% 100.0
LVEDP  12 mmHg 20.0
No. diseased vessels 2.7  0.1
Operative data
No. of grafts 2.8  0.1
CPB duration (min) 72.4  3.5
AXC duration (min) 36.1  3.2
Abbreviations: NIDDM, noninsulin-dependent diabetes mellitus; NS
lar ejection fraction; LVEDP, left ventricular end-diastolic pressure; S
Table 2. Peak cTn-I Concentrations for Non-PMI and P-MI Groups
No. of Patients
(%) Peak cTn-I
Hours After
reperfusion
Non-PMI 40 (57.1) 7.1  4.3 g/L 8.6  5.6
Non–Q-wave PMI 7 (10.0) 27.2  13.3 g/L 12.9  8.1a
Q-wave PMI 2 (2.9) 67.3  36.4 g/L 33.0  21.2erifying the reference range calculated from confidence inter-
als above. The cTn-I data from the non-PMI and PMI patient
roups were plotted to generate an ROC curve for the ability of
I, Undefined, and PMI Groups
Undefined PMI p Value
21 (30.0) 9 (12.9)
90.5% male 100% male NS (0.62)
62.0  1.4 61.1  2.9 NS (0.33)
78.6  2.3 79.7  3.6 NS (0.90)
38.1 22.2 NS (0.70)
4.8 0.0 NS (0.35)
68.4 88.9 NS (0.44)
80.9 88.9 NS (0.39)
38.1 66.7 NS (0.63)
42.9 66.7 NS (0.45)
14.3 0 NS (0.50)
9.5 33.3 NS (0.08)
57.1 66.7 NS (0.48)
NS (0.96)
66.7 55.6
33.3 44.4
47.6 44.4 NS (0.41)
28.6 22.2 NS (0.72)
100.0 100.0 NS (1.00)
9.5 22.2 NS (0.53)
2.7  0.1 2.8  0.2 NS (0.92)
2.7  0.1 2.8  0.2 NS (0.91)
75.0  5.7 85.7  6.4 NS (0.30)
38.4  3.4 48.6  4.2 NS (0.18)
significant; ACE, angiotensin-converting enzyme; LVEF, left ventric-
, segmental wall motion abnormality; AXC, aortic cross-clamp.on-PM
, notFig 3. ROC curve showing utility of cTn-I for the diagnosis of PMI
fter elective CABG surgery.
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292 MARTIN ET ALTn-I to detect PMI (Fig 3). Using the upper-left corner of the
urve, a value of 15 g/L was defined as the cut point for PMI.
his value had a sensitivity (true-positive rate) of 92.5% and a
pecificity (true-negative rate) of 88.9%. An area under the
OC curve of 0.975 represents excellent assay utility.
Using 15 g/L as the cut point value, as suggested by both
he ROC curve and the confidence interval (97.5th percentile)
ethods, the authors reclassified the 21 patients in the “unde-
ned” group into either the non-PMI (peak cTn-I15 g/L) or
MI (peak cTn-I 15 g/L) groups. This resulted in a diag-
osis of PMI in 25 of the 70 patients (35.7%) in the present
tudy population.
When PMI was defined using the cutpoint 15 g/L for
Tn-I, the authors noted that ECG changes were inconsistent,
ith 36.0% (9/25) false negative (according to cTn-I criteria
ailed to show new postoperative ECG changes indicative of
MI) and 17.8% (8/45) false-positive incidence of PMI after
urgery. CK-MB levels showed better diagnostic utility than
CG, with 8.0% (2/25) false-negative and 15.6% (7/45) false-
ositive incidence of PMI after surgery.
The requirement for cardiovascular support and the inci-
ence of postoperative complications are summarized in Table
. Requirement for inotropic support was significantly in-
reased in the PMI group. Although more patients in the PMI
roup experienced arrhythmia, this did not reach statistical
ignificance.
DISCUSSION
The aim of this study was 2-fold: (1) to compare the corre-
ation between 2 commercially available cTn-I assay systems
nd (2) to identify a value for cTn-I above which the authors
ould be fairly certain that a patient had sustained an ischemic
yocardial injury after CABG surgery. In keeping with data by
ao et al,27 the authors report a significant difference between
he AxSYM and Opus Plus assay systems. By using certain
haracteristics of the Gaussian distribution and then confirming
ndings with a second, independent methodology (ROC curve
nalysis), a cut point (15 g/L, Opus Plus) was established
hat is indicative of ischemic myocardial injury after CABG
urgery.
The role of cTn-I for the diagnosis of PMI7,8,10,14-17 is now
ell established; however, the fact that the authors and others
eport different values between commercially available cTn-I
ssay systems and the fact that the upper reference values differ
ignificantly between various studies7,15,17 serves to further
ighlight the need for individual centers to determine reference
anges suitable to their clinical environment; that is, until such
Table 3. Perioperative Complicatio
Non-PMI
Inotropic support (%) 6.6
Rhythm disturbance (%) 32
Ventilation (h) 6.6  0.9
ICU-LOS (h) 20.4  4.7 2
Hospital LOS (d) 6.3  0.4
Abbreviations: CI, confidence interval; LOS, length of stay.ime as cTn-I assay systems, surgical techniques (on-pump v Eff-pump OPCAB), and cardioprotective strategies are stan-
ardized.
The authors noted a clear proportional bias between the 2
ssay systems used in this study. This is of concern when a high
alue for a test is presumably indicative of increasing severity
f pathology. If a laboratory changes its assay without warning
hen there is the possibility for over- or, even worse, underdi-
gnosis of PMI, especially because the adverse relationship that
xists between PMI and patient outcome1-9,17 is increasingly
ecognized and may warrant early intervention. Accordingly,
n overall PMI rate of 35.7% in this series of patients was
eported. The authors believe that this is a more accurate
stimate of perioperative myocardial injury than previously
ublished estimates3,4,6 because it includes all grades of isch-
mic injury rather than just transmural MIs. The authors found
hat a cTn-I value of 15 g/L had a sensitivity (true-positive
ate) of 92.5% and a specificity (true-negative rate) of 88.9%
or the diagnosis of PMI, which the authors believe are accept-
ble parameters for use in routine clinical practice. The area
nder the ROC curve of 0.975 supports this premise. Although
his is not a study of cardioplegia methods, these data suggest
ardioprotective strategies may be improved.
A major limitation of this study is the lack of a true diag-
ostic gold standard to compare with the troponin measurement
ecause ECG changes and CK-MB levels are inaccurate in this
etting. This is supported by Van Velde et al28 who showed
oor concordance between changes in enzyme activity (CK,
K-MB, aspartate aminotransferase, and the lactate dehydro-
enase-1/lactate dehydrogenase-2 ratio) and ultimate evidence
f PMI at autopsy after cardiac surgery. In the present series,
CG changes alone would have led to an erroneous diagnosis
egarding PMI more than half of the time.
It is expected that biomarker release will occur in all
atients during cardiac surgery (related to both ischemic and
urgical injury) and therefore an attempt to differentiate
rocedural injury from true ischemic injury by defining
iomarker release in the reference control group (those
ithout PMI according to CK-MB and ECG criteria) may
ave been facilitated by the use of echocardiographic or
ther imaging criteria.
Other limitations to this study include the fact that the
redefined criteria for PMI differ from those published in the
onsensus document of the Joint European Society of Car-
iology/American College of Cardiology Committee for re-
efinition of myocardial infarction.10 That said, the compre-
ensive guidelines within the consensus document focus
redominantly on the nonsurgical setting and the criteria for
d Duration of Postoperative Care
p Value Relative Ratio (95% CI)
0.03 4.2 (1.2-14.8)
0.58 1.3 (0.6-2.8)
0.5 0.10
2.0 0.94
0.3 0.76ns an
PMI
28
76
5.0 
0.0 
6.4 CG and CK-MB changes, as supported by the cardiac
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293TROPONIN I ASSAY SYSTEMSurgery literature, differ only slightly from those proposed.
xamples of minor differences include the following: a
-wave MI was defined as a Q-wave duration 0.04 sec-
nds, whereas the consensus document proposes a Q-wave
uration 0.03 seconds. CK-MB levels significant for PMI
ere set at twice the upper reference limit, similar to that
roposed for total CK by the consensus document, whereas
he consensus document recommends that significant
K-MB values are those that exceed the 99th percentile of
K-MB values in a reference control group.
Finally, because the patient population was relatively
ealthy, with normal ejection fractions, and few postoperative
orbid events, this study is underpowered from a clinicalutcome point of view. Nevertheless, having established a c
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1eference range for cTn-I elevation after CABG surgery for the
uthors’ institution, the authors now have the ability to corre-
ate a possible relationship between severity of elevated cTn-I
ith timing of elevation (Table 2) and adverse clinical outcome
n a future adequately powered study. Furthermore, the authors
rovide a description of a method, which is simple to reproduce
sing tests that are already available and which are self-con-
rmatory, so busy units may verify for themselves that their
aboratory and clinical impressions are accurate. It does not
equire large numbers of patients or tests per patient and thus is
ffordable. This may allow centers to establish a local baseline
ncidence of myocardial injury after elective CABG surgery,
gainst which newer myocardial protective strategies can be
ompared.REFE
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